Technical Analysis for OKYO - OKYO Pharma Limited
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| C | 1.07 | 3.88% | 0.04 |
OKYO closed up 3.88 percent on Wednesday, November 20, 2024, on 85 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 50 DMA | Bullish | 0.00% | |
| Stochastic Buy Signal | Bullish | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 3.88% | |
| NR7 | Range Contraction | 3.88% | |
| Gapped Up | Strength | 3.88% | |
| Oversold Stochastic | Weakness | 3.88% | |
| MACD Bearish Centerline Cross | Bearish | 4.90% |
| Alert | Time |
|---|---|
| Up 2% | about 21 hours ago |
| Up 1% | about 21 hours ago |
| Possible NR7 | 1 day ago |
| Up 3% | 2 days ago |
| Up 2% | 2 days ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 09/30/2024
OKYO Pharma Limited (Nasdaq: OKYO, LSE: OKYO) is a biotechnology company developing next-generation therapeutics to improve the lives of patients suffering from inflammatory eye diseases and ocular pain. OKYO’s research program is focused on a novel G Protein-Coupled Receptor, or GPCR, which OKYO believes plays a key role in the pathology of these inflammatory eye diseases of high unmet medical need. OKYO’s therapeutic approach is focused on targeting inflammatory and pain modulation pathways that drive these conditions. The Company is presently developing OK-101, its lead preclinical product candidate, for the treatment of dry-eye disease “DED”. The Company also plans to evaluate its potential in benefiting patients with ocular neuropathic pain, uveitis and allergic conjunctivitis.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Clinical Medicine Immunology Pain Eye Diseases Inflammatory Uveitis Allergic Conjunctivitis Dry Eye Disease Conjunctivitis Measles Treatment Of Dry Eye Disease
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Clinical Medicine Immunology Pain Eye Diseases Inflammatory Uveitis Allergic Conjunctivitis Dry Eye Disease Conjunctivitis Measles Treatment Of Dry Eye Disease
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 2.12 |
| 52 Week Low | 0.8075 |
| Average Volume | 65,159 |
| 200-Day Moving Average | 1.27 |
| 50-Day Moving Average | 1.06 |
| 20-Day Moving Average | 1.12 |
| 10-Day Moving Average | 1.08 |
| Average True Range | 0.08 |
| RSI (14) | 48.19 |
| ADX | 25.85 |
| +DI | 20.61 |
| -DI | 15.59 |
| Chandelier Exit (Long, 3 ATRs) | 1.11 |
| Chandelier Exit (Short, 3 ATRs) | 1.21 |
| Upper Bollinger Bands | 1.23 |
| Lower Bollinger Band | 1.00 |
| Percent B (%b) | 0.29 |
| BandWidth | 20.29 |
| MACD Line | -0.01 |
| MACD Signal Line | 0.00 |
| MACD Histogram | -0.0126 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.19 | ||||
| Resistance 3 (R3) | 1.19 | 1.14 | 1.17 | ||
| Resistance 2 (R2) | 1.14 | 1.11 | 1.14 | 1.16 | |
| Resistance 1 (R1) | 1.11 | 1.09 | 1.12 | 1.11 | 1.16 |
| Pivot Point | 1.06 | 1.06 | 1.07 | 1.06 | 1.06 |
| Support 1 (S1) | 1.03 | 1.03 | 1.05 | 1.03 | 0.98 |
| Support 2 (S2) | 0.98 | 1.01 | 0.99 | 0.98 | |
| Support 3 (S3) | 0.95 | 0.98 | 0.97 | ||
| Support 4 (S4) | 0.95 |
